NTI164 Phase II/III Autism Data Accepted for Publication

Jul 29, 2026 at 7:00 PM EDT · Issued by Neurotech International Ltd. via ASX

Filed with ASX · Jul 29, 2026 at 7:00 PM EDT

On 6ix: 6ix.com/news/nti164-phase-iiiii-autism-data-accepted-for-publication

ASX Announcement Neurotech International Ltd Suite 102 / Level 1, 55 Collins Street, Melbourne, VIC 3000 T : 03 9498 3132 E: info@neurotechinternational.com W: neurotechinternational.com ABN: 73 610 205 402 ASX: NTI 1 of 2 30 July 2026 NTI164 HARMONY STUDY - ...

View Attachment

6ix hasn’t read this filing yet.

Neurotech International Ltd. on 6ix

Earlier from Neurotech International

Neurotech secures $3.15 million R&D tax incentive loanJul 14
US FDA clears IND for NTI164Jul 13
NTI secures Notices of Allowance for US patent applicationsJul 1
NTI initiates First Clinical Site for Phase 3 ASD TrialMar 16
Appendix 4D & Half Year ReportFeb 26

Later from Neurotech International

Trading HaltJul 30
Quarterly Activities/Appendix 4C Cash Flow ReportJul 30
Proposed issue of securities - NTIAug 3
Receipt of Binding Commitments for $4.5m PlacementAug 3
Application for quotation of securities - NTIAug 11

All Neurotech International news releases

Follow Neurotech International into a list and get an email when it puts out news.

Follow Neurotech International